Community Advisory Board

Readers Rep

Markets:

Overview

News

Currencies

International

Treasuries

Bristol-Myers Squibb (NY:BMY)

56.23 +0.56 (+1.01%)

Streaming Delayed Price Updated: 10:56 AM EDT, May 12, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Bristol-Myers Squibb

< Previous 1 2 3 4 5 6 7 8 9

...

68 69 Next >

Bristol-Myers Squibb (BMY): Buy, Sell, or Hold Post Q1 Earnings?

Today 0:01 EDT

Bristol-Myers Squibb has had an impressive run over the past six months as its shares have beaten the S&P 500 by 5.7%. The stock now trades at $55.77, markin...

Via StockStory

Topics Stocks

Is Bristol Myers Squibb Stock Overvalued at Nearly $60? A Reality Check for Value Investors. ↗

May 11, 2026

This may be an excellent deal for those focused on the long game.

Via The Motley Fool

Topics Intellectual Property

Bristol Myers Squibb Touts Pipeline Gains as Shareholders Back Board at Annual Meeting ↗

May 10, 2026

Bristol Myers Squibb (NYSE:BMY) used its 2026 annual meeting of shareholders to highlight progress in its growth portfolio, pipeline development, balance sheet management and cost-saving initiatives,...

Via MarketBeat

Bristol Myers Squibb (NYSE:BMY) Q1 2026 Earnings Beat Driven by Growth Portfolio ↗

April 30, 2026

Via Chartmill

Topics Earnings

Bristol-Myers Squibb’s Q1 Earnings Call: Our Top 5 Analyst Questions

May 07, 2026

Bristol-Myers Squibb’s first quarter results were notably shaped by ongoing momentum in its growth portfolio and steady execution across key marketed product...

Via StockStory

Topics Earnings

1 Healthcare Stock with Competitive Advantages and 2 Facing Challenges

May 06, 2026

From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. But financial performance has lagged...

Via StockStory

BMY Q1 Deep Dive: Growth Portfolio, Pipeline Milestones, and Anticipated Late-Stage Readouts

May 01, 2026

Biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) announced better-than-expected revenue in Q1 CY2026, with sales up 2.6% year on year to $11.49 bill...

Via StockStory

Why Bristol Myers Squibb Stock Rocked the Market Today ↗

April 30, 2026

It scored crushing beats on both revenue and profitability in its first quarter.

Via The Motley Fool

Bristol Myers (BMY) Q1 2026 Earnings Transcript ↗

April 30, 2026

Bristol Myers (BMY) Q1 2026 Earnings Transcript

Via The Motley Fool

Bristol-Myers Squibb (NYSE:BMY) Exceeds Q1 CY2026 Expectations

April 30, 2026

Biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) announced better-than-expected revenue in Q1 CY2026, with sales up 2.6% year on year to $11.49 bill...

Via StockStory

Earnings To Watch: Bristol-Myers Squibb (BMY) Reports Q1 Results Tomorrow

April 28, 2026

Biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) will be reporting earnings this Thursday before market open. Here’s what investors should know. Bri...

Via StockStory

3 Healthcare Stocks That Pay You While You Wait for the Growth ↗

April 27, 2026

It may not seem like it at first, but these dividends are safe.

Via The Motley Fool

Topics Intellectual Property

3 Biotech Stocks That Could Benefit from the Patent Cliff ↗

April 27, 2026

Via MarketBeat

Topics Intellectual Property

Is Bristol Myers Squibb the Best Bargain in Big Pharma? ↗

April 27, 2026

This pharma stock is cheap for a reason.

Via The Motley Fool

Topics Intellectual Property

Bristol Myers Squibb: Low Volatility Meets High Dividend Yield ↗

April 26, 2026

Volatility and dividend yield are important metrics for investors thinking about a long-term buy.

Via The Motley Fool

Topics Intellectual Property

3 Healthcare Stocks That Pay You a Dividend While You Wait for a Recovery ↗

April 25, 2026

As you wait for stock prices to rebound, these three healthcare companies pay dividends with generous yields.

Via The Motley Fool

Topics Intellectual Property World Trade

April 22, 2026

Wall Street has issued downbeat forecasts for the stocks in this article. These predictions are rare - financial institutions typically hesitate to say bad t...

Via StockStory

2 Healthcare Stocks to Buy and 1 to Approach With Caution ↗

April 15, 2026

Recent performances don't tell the whole story.

Via The Motley Fool

J&J Shatters Estimates as Oncology and MedTech Power 2026 Outlook Higher

April 15, 2026

Johnson & Johnson (NYSE: JNJ) delivered a robust first-quarter 2026 earnings report on April 14, 2026, handily beating Wall Street expectations and signaling a successful navigation of the long-feared...

Via MarketMinute

Topics Economy Intellectual Property

The RAS Revolution: A Deep Dive into Revolution Medicines’ Path to Dominance (2026 Report)

April 14, 2026

As of today, April 14, 2026, the biotechnology landscape is being reshaped by a singular clinical milestone that many once deemed impossible. Just twenty-four hours ago, Revolution Medicines, Inc....

Via Finterra

Topics Economy Initial Public Offering Intellectual Property

Which Dividend Pharma Stock Should a Value Investor Choose Today? ↗

April 12, 2026

Bristol Myers Squibb looks like a value buy, so long as its pipeline remains strong.

Via The Motley Fool

Topics Intellectual Property

2 Recession Resistant Dividend Stocks to Buy Now While They're Still Cheap ↗

April 10, 2026

Healthcare never sleeps.

Via The Motley Fool

Topics Economy Intellectual Property

Neurocrine Biosciences (NBIX): A New Era in Neuroscience and Endocrinology

April 07, 2026

Date: April 7, 2026 Introduction Neurocrine Biosciences, Inc. (NASDAQ: NBIX) has long been a bellwether for the mid-cap biotechnology sector, serving as a primary case study in how a company can...

Via Finterra

Topics Earnings Economy Intellectual Property

Lilly’s $47.8 Billion Bet: Why the Contessa Acquisition Redefines the Future of Medicine

April 06, 2026

In a move that has sent shockwaves through both the pharmaceutical and technology sectors, Eli Lilly and Company (NYSE: LLY) announced today, April 6, 2026, the finalized acquisition of Contessa, a...

Via MarketMinute

Topics Artificial Intelligence

Gilead Extends Tender Offer for Arcellx as Biotech M&A Sentiment Faces a Reality Check

April 06, 2026

Gilead Sciences (NASDAQ: GILD) announced a strategic extension of its tender offer to acquire cell therapy innovator Arcellx (NASDAQ: ACLX) on April 1, 2026. Originally scheduled to expire on April 2,...

Via MarketMinute

AMN Healthcare Services, DaVita, Bristol-Myers Squibb, Novavax, and AbbVie Shares Plummet, What You Need To Know

April 02, 2026

What Happened? A number of stocks fell in the afternoon session after reports revealed that the US may impose up to 100% tariffs on imports of branded and pa...

Via StockStory

Topics Government Stocks World Trade

The Trillion-Dollar Treatment: A Deep Dive into Eli Lilly and Company (LLY)

April 02, 2026

As of April 2, 2026, Eli Lilly and Company (NYSE:LLY) stands as the preeminent titan of the global healthcare sector. Historically recognized as a steady, century-old pharmaceutical giant, the company...

Via Finterra

Topics Artificial Intelligence Economy Intellectual Property

3 Value Stocks Walking a Fine Line

April 02, 2026

Value stocks typically trade at discounts to the broader market, offering patient investors the opportunity to buy businesses when they’re out of favor. The ...

Via StockStory

Moderna 2.0: The mRNA Pioneer’s Pivot to Oncology and the Path to 2028 Profitability

March 31, 2026

As of March 31, 2026, Moderna Inc. (NASDAQ: MRNA) finds itself at a defining historical junction. After years of being defined by a single, world-altering product—its COVID-19 vaccine—the...

Via Finterra

Topics Initial Public Offering

United Therapeutics Surges 14% on Groundbreaking Tyvaso Phase 3 Results for IPF

March 31, 2026

In a landmark moment for respiratory medicine and biotechnology, United Therapeutics (NASDAQ:UTHR) announced late Monday, March 30, 2026, that its pivotal TETON-1 Phase 3 study for nebulized Tyvaso...

Via MarketMinute

< Previous 1 2 3 4 5 6 7 8 9

...

68 69 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

About Us

Bristol-Myers Squibb (NY:BMY)

Headline News about Bristol-Myers Squibb